参松养心胶囊联合替米沙坦片、酒石酸美托洛尔片治疗高血压合并心律失常患者的临床疗效

doi:10.3969/j.issn.1671-7171.2026.06.019

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1254 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the clinical efficacy of Shensong Yangxin Capsule combined with telmisartan tablets and metoprolol tartrate tablets in the treatment of hypertensive patients complicated with arrhythmia. 【Methods】 A total of 104 hypertensive patients combined with arrhythmia admitted to our hospital from February 2024 to June 2025 were selected and divided into control group and observation group by random number table method, with 52 cases in each group. The control group received telmisartan tablets combined with metoprolol tartrate tablets tartrate, and the observation group was given Shensong Yangxin Capsule on the basis of the treatment for the control group. The two groups were compared in terms of clinical efficacy, blood pressure [diastolic blood pressure (DBP), systolic blood pressure (SBP)], cardiac function indicators [left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF)] and incidence of adverse reactions. 【Results】 The total clinical effective rate of the observation group was 94.23% (49/52), which was higher than 75.00% (39/52) of the control group, and the difference was statistically significant (χ²=7.386, P<0.05). After treatment, DBP and SBP in both groups were lower than those before treatment, and the levels in the observation group were lower than those in the control group, with statistically significant differences (P<0.05). After treatment, LVEDD and LVESD of the two groups were decreased and LVEF was increased compared with those before treatment; LVEDD and LVESD in the observation group were lower, while LVEF was higher than those in the control group, and all differences had statistical significance (all P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (χ²=0.377, P＞0.05). 【Conclusion】 Shensong Yangxin Capsule combined with telmisartan tablets and metoprolol tartrate tablets can obviously improve cardiac function of hypertensive patients complicated with arrhythmia, with good clinical efficacy and high safety.

Key words： Hypertension Arrhythmias, Cardiac Shensong Yangxin Capsules Telmisartan Metoprolol

Received: 24 October 2025

PACS:

R544.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FAN Lili

Cite this article:

FAN Lili. Clinical Efficacy of Shensong Yangxin Capsule Combined with Telmisartan Tablets and Metoprolol Tartrate Tablets in the Treatment of Hypertensive Patients Complicated with Arrhythmia[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(6): 948-950.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.06.019 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I6/948

[1] 王姣,郎月,崔婷婷,等.奥美沙坦酯氨氯地平片治疗老年原发性高血压的临床疗效及安全性[J].医学临床研究,2025,42(7):1257-1259.
[2] WANDER G S, RAM B, KUMAR SONKAR S,et al.Comparison of the efficacy, safety, and tolerability of the FDC of telmisartan + bisoprolol with telmisartan + metoprolol succinate ER combination therapy for stage 1 and stage 2 hypertension: a double-blind, multicentric, phase-Ⅲ clinical study[J].Indian Heart J,2024,76(3):159-166.
[3] 王萍,黎民,罗申.参松养心胶囊联合厄贝沙坦对提升高血压心脏病致心律失常康复效率的研究[J].罕少疾病杂志,2025,32(2):76-78.
[4] 郭宝亮,李占鲁,李晓娜.参松养心胶囊联合酒石酸美托洛尔治疗心力衰竭合并室性心律失常的有效性与安全性[J].中国药师,2023,26(10):104-110.
[5] 杨杰,郑广生,李垚,等.参松养心胶囊联合胺碘酮治疗冠心病室性心律失常患者的疗效及对心肌指标的影响[J].中国药物应用与监测,2025,22(4):696-699.
[6] 李志强,张瑜,牛景霞,等.参松养心胶囊联合二丁酰环磷腺苷钙治疗心力衰竭合并心律失常的效果及对血清MMP-9、BNP、ALD水平的影响[J].疑难病杂志,2025,24(7):799-803.
[7] 杜腾飞,杨钦超,柳敏,等.联用参松养心胶囊与胺碘酮治疗心力衰竭合并室性心律失常的有效性及安全性探讨[J].黑龙江医药科学,2025,48(8):79-80.
[8] 中国高血压防治指南修订委员会,高血压联盟(中国),中国医疗保健国际交流促进会高血压病学分会,等. 中国高血压防治指南(2024年修订版)[J].中华高血压杂志(中英文),2024, 32(7):603-700.
[9] 中华医学会心血管病学分会, 中国生物医学工程学会心律分会, 中国医师协会循证医学专业委员会, 等.心律失常紧急处理专家共识[J].中华心血管病杂志,2013,41(5):363-376.
[10] 戴秋艳.高血压与心律失常2017年欧洲专家共识解读[J].内科理论与实践,2018,13(1):20-23.
[11] 李晓丹,张宝翠,李丽晶,等.吲达帕胺联合厄贝沙坦对高血压并发充血性心力衰竭患者的疗效及凝血-纤溶系统的影响[J].西部医学,2021,33(7):1060-1064.
[12] 陈云江,龚艳春.氨氯地平联合厄贝沙坦不同给药时间对原发性高血压病人血压变异性和血压晨峰现象的影响[J].安徽医药,2021,25(6):1236-1239.
[13] 黄伟鹏.美托洛尔联合厄贝沙坦治疗高血压合并心律失常患者的临床疗效及其对血压、心功能的影响[J].临床合理用药杂志,2022,15(9):67-70.
[14] 李西红,孙黎博. 胺碘酮联合美托洛尔治疗急性心肌梗死合并心律失常患者的效果及对患者心脏功能的影响分析[J].山西医药杂志,2019,48(22):2734-2737.
[15] 印章,付永波,朱冬梅,等. 替米沙坦联合西尼地平治疗原发性高血压的疗效[J].西北药学杂志,2024,39(6):201-206.
[16] 任园园.参松养心胶囊联合缬沙坦治疗高血压伴永久性房颤临床观察[J].实用中医药杂志,2025,41(3):610-613.